BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 33151508)

  • 1. Diabetic ketoacidosis in patients treated with SGLT2 inhibitors: experience at a tertiary hospital.
    Papanastasiou L; Glycofridi S; Gravvanis C; Skarakis N; Papadimitriou I; Kanti G; Kapsali C; Kounadi T
    Hormones (Athens); 2021 Jun; 20(2):369-376. PubMed ID: 33151508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
    Burke KR; Schumacher CA; Harpe SE
    Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission.
    Hamblin PS; Wong R; Ekinci EI; Fourlanos S; Shah S; Jones AR; Hare MJL; Calder GL; Epa DS; George EM; Giri R; Kotowicz MA; Kyi M; Lafontaine N; MacIsaac RJ; Nolan BJ; O'Neal DN; Renouf D; Varadarajan S; Wong J; Xu S; Bach LA
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3077-3087. PubMed ID: 30835263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
    Wang L; Voss EA; Weaver J; Hester L; Yuan Z; DeFalco F; Schuemie MJ; Ryan PB; Sun D; Freedman A; Alba M; Lind J; Meininger G; Berlin JA; Rosenthal N
    Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1620-1628. PubMed ID: 31456304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
    Musso G; Sircana A; Saba F; Cassader M; Gambino R
    PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hospitalization of Patients With Diabetes Due to Ketoacidosis Before and After the Initiation of Sodium-Glucose Cotransporter-2 Inhibitors.
    Pikielny PR; Lurie TH; Rabia R; Twito O; Rosenblum RH; Yoseph LB
    Endocr Pract; 2023 Sep; 29(9):686-691. PubMed ID: 37442436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose cotransport-2 inhibitor induced ketoacidosis following coronary artery bypass surgery: implications for management.
    McCann M; O'Brien A; Larbalestier R; Davis T
    Intern Med J; 2022 May; 52(5):876-879. PubMed ID: 35538006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium Glucose Cotransporter-2 Inhibitor Treatment and the Risk of Diabetic Ketoacidosis in Denmark: A Retrospective Cohort Study of Five Years of Use.
    Laursen HVB; Røikjer JB; Dal J; Jensen MH
    Curr Drug Saf; 2021; 16(1):73-81. PubMed ID: 32814538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and Clinical Characteristics of Adults Presenting With Sodium-Glucose Cotransporter-2 Inhibitor-Associated Diabetic Ketoacidosis at a Canadian Academic Tertiary Care Hospital.
    Clark A; Mohammed AS; Raut A; Moore S; Houlden R; Awad S
    Can J Diabetes; 2021 Apr; 45(3):214-219. PubMed ID: 33046401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Life-Threatening Complications Related to Delayed Diagnosis of Euglycemic Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Report of 2 Cases.
    Goto S; Ishikawa JY; Idei M; Iwabuchi M; Namekawa M; Nomura T
    Am J Case Rep; 2021 Mar; 22():e929773. PubMed ID: 33723205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-Glucose Cotransporter-2 Inhibitor-associated Euglycemic Diabetic Ketoacidosis: Lessons From a Case Series of 4 Patients Undergoing Coronary Artery Bypass Grafting Surgery.
    Chaudhry A; Roels C; Lee J
    Can J Diabetes; 2022 Dec; 46(8):843-850. PubMed ID: 36068154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review.
    Bamgboye AO; Oni IO; Collier A
    Eur J Clin Pharmacol; 2021 May; 77(5):651-657. PubMed ID: 33244632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Euglycemic diabetic ketoacidosis associated with SGLT2i use: Case series.
    Puls HA; Haas NL; Franklin BJ; Theyyunni N; Harvey CE
    Am J Emerg Med; 2021 Jun; 44():11-13. PubMed ID: 33571749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Population-Based Study of SGLT2 Inhibitor-Associated Postoperative Diabetic Ketoacidosis in Patients with Type 2 Diabetes.
    Lui DTW; Wu T; Au ICH; Liu X; Fung MMH; Lee CH; Fong CHY; Woo YC; Lang BHH; Tan KCB; Wong CKH
    Drug Saf; 2023 Jan; 46(1):53-64. PubMed ID: 36289137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases].
    Menghoum N; Oriot P; Hermans MP; Mariage JL
    Rev Med Interne; 2020 Apr; 41(4):226-231. PubMed ID: 31866073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On-label use of sodium-glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes.
    Horii T; Oikawa Y; Atsuda K; Shimada A
    J Diabetes Investig; 2021 Sep; 12(9):1586-1593. PubMed ID: 33448127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of SGLT2 inhibitors in individuals with type 1 diabetes under continuous subcutaneous insulin infusion: a real-world study.
    Silva VB; Fonseca L; Duarte DB; Puga FM; Assuncao G; Garrido S; Teixeira S; Vilaverde J; Cardoso MH
    Endocr Regul; 2023 Jan; 57(1):144-151. PubMed ID: 37561831
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors.
    Jeon JY; Kim SK; Kim KS; Song SO; Yun JS; Kim BY; Kim CH; Park SO; Hong S; Seo DH; Seo JA; Noh JH; Kim DJ;
    Diabetes Metab; 2019 Oct; 45(5):453-457. PubMed ID: 30639566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors.
    Fleming N; Hamblin PS; Story D; Ekinci EI
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32302001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
    Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
    Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.